News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SanguiBioTech GmbH And German Pharmaceutical Company Plan Joint Development Of Haemoglobin Wound Spray



10/19/2005 5:08:47 PM

A renowned German medium sized pharmaceutical company and SanguiBioTech GmbH of Witten, Germany, a wholly owned subsidiary of Sangui BioTech International, Inc. (NASD OTCBB: SGBI), have declared their intention to jointly develop a haemoglobin wound spray based on Sangui's artificial oxygen carrier for the treatment of chronic wounds. The product has undergone a number of initial clinical experiments which give rise to the expectation that the new product may revolutionize the treatment of chronic wounds.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES